Brief: Orchestra Biomed Receives FDA Approval Of Ide To Initiate U.S. Coronary Pivotal Trial Randomizing First-In-Class Sirolimus-Angioinfusion Balloon, Virtue Sab, Head-To-Head With Paclitaxel-Coated Balloon

Orchestra Biomed Holdings

29/04/2025 14:20

April 29 (Reuters) - Orchestra Biomed Holdings Inc OBIO.O:

ORCHESTRA BIOMED RECEIVES FDA APPROVAL OF IDE TO INITIATE U.S. CORONARY PIVOTAL TRIAL RANDOMIZING FIRST-IN-CLASS SIROLIMUS-ANGIOINFUSION BALLOON, VIRTUE SAB, HEAD-TO-HEAD WITH PACLITAXEL-COATED BALLOON

ORCHESTRA BIOMED HOLDINGS INC: TARGETING INITIATION OF VIRTUE TRIAL DURING SECOND HALF OF 2025

Source text: ID:nGNX9CRyqk

Further company coverage: OBIO.O

 ((Reuters.Briefs@thomsonreuters.com;))